Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C W Lees

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Alimentary Pharmacology & Therapeutics|July 20, 2007
A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitisC W Lees, D Heys, G T Ho, et al.
Alimentary Pharmacology & Therapeutics|December 18, 2007
The use of adalimumab in the management of refractory Crohn's diseaseG-T Ho, L Smith, S Aitken, et al.
Inflammatory Bowel Diseases|November 20, 2009
Magnetic resonance follow-through imaging for evaluation of disease activity in ileal Crohn's disease: an observational, retrospective cohort studyC A Parisinos, V E D McIntyre, T Heron, et al.
Gut|June 5, 2008
Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitisC L Noble, A R Abbas, J Cornelius, et al.
Alimentary Pharmacology & Therapeutics|October 9, 2013
The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness methodW Reinisch, Y Chowers, S Danese, et al.
Alimentary Pharmacology & Therapeutics|February 3, 2009
Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008)G T Ho, A Mowat, L Potts, et al.
Alimentary Pharmacology & Therapeutics|January 10, 2009
The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-upC W Lees, A I Ali, A I Thompson, et al.
Inflammatory Bowel Diseases|February 8, 2007
Contribution of the NOD1/CARD4 insertion/deletion polymorphism +32656 to inflammatory bowel disease in Northern EuropeJ Van Limbergen, R K Russell, E R Nimmo, et al.
Alimentary Pharmacology & Therapeutics|February 20, 2016
Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysisN A Kennedy, B Warner, E L Johnston, et al.
Alimentary Pharmacology & Therapeutics|October 7, 2014
Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patientsN A Kennedy, R Kalla, B Warner, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Alimentary Pharmacology & Therapeutics|July 20, 2007
A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitisC W Lees, D Heys, G T Ho, et al.
Alimentary Pharmacology & Therapeutics|December 18, 2007
The use of adalimumab in the management of refractory Crohn's diseaseG-T Ho, L Smith, S Aitken, et al.
Inflammatory Bowel Diseases|November 20, 2009
Magnetic resonance follow-through imaging for evaluation of disease activity in ileal Crohn's disease: an observational, retrospective cohort studyC A Parisinos, V E D McIntyre, T Heron, et al.
Gut|June 5, 2008
Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitisC L Noble, A R Abbas, J Cornelius, et al.
Alimentary Pharmacology & Therapeutics|October 9, 2013
The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness methodW Reinisch, Y Chowers, S Danese, et al.
Alimentary Pharmacology & Therapeutics|February 3, 2009
Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008)G T Ho, A Mowat, L Potts, et al.
Alimentary Pharmacology & Therapeutics|January 10, 2009
The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-upC W Lees, A I Ali, A I Thompson, et al.
Inflammatory Bowel Diseases|February 8, 2007
Contribution of the NOD1/CARD4 insertion/deletion polymorphism +32656 to inflammatory bowel disease in Northern EuropeJ Van Limbergen, R K Russell, E R Nimmo, et al.
Alimentary Pharmacology & Therapeutics|February 20, 2016
Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysisN A Kennedy, B Warner, E L Johnston, et al.
Alimentary Pharmacology & Therapeutics|October 7, 2014
Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patientsN A Kennedy, R Kalla, B Warner, et al.
Pageof 3